glp-1 news 2025 november You've probably seen the about the recent TrumpRx announcement — here's what it actually means if you're on or considering GLP-1s 👇 The deal between TrumpRx, Eli Lilly, and Novo Nordisk GLP-1 Agonists For Obesity In

Brierley DI, de Lartigue G

Liraglutide in a once-daily dose of 1.8 mg was shown to reduce the risk of major adverse cardiovascular events in patients with type 2 diabetes and high cardiovascular disease risk in the Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER) trial published in 2016 (19)

Use of metformin in the index date was defined by having a prescription for metformin issued in the 60 days before the index date

Coverage is shifting rapidly

For more background on GLP-1 science and medical context, read a clinical overview of semaglutide here: Real-world effectiveness: what reviews and studies say Evidence base for injectable semaglutide and tirzepatide is robust, showing substantial weight loss in trials and real-world use

Identifying and limiting gas-producing foods that may worsen symptoms is helpful